A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients

J. A. Frank, N. Richert, B. Lewis, C. Bash, T. Howard, R. Civil, R. Stone, J. Eaton, H. McFarland, T. Leist

Research output: Contribution to journalArticle

Abstract

The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-I (rhIGF-I) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sclerosis (MS) patients. Monthly clinical and MRI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-I. The primary outcome measure was contrast enhancing lesion (CEL) frequency on treatment compared to baseline. Secondary outcome measures included clinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), TI-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regional metabolite ratios. rhIGF-I (Cephalon) was administered at a dose of 50 mg subcutaneously twice a day for 6 months. rhIGF-I was safe and well tolerated with no severe adverse reactions. There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity. Although rhIGF-I did not alter the course of disease in this small cohort of MS patients, the drug was well tolerated. Further studies using rhIGF-I alone or in combination with other therapies may be of value because of the proposed mechanism of action of this growth factor on the oligodendrocyte and remyelination.

Original languageEnglish (US)
Pages (from-to)24-29
Number of pages6
JournalMultiple Sclerosis
Volume8
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Multiple Sclerosis
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Oligodendroglia
Therapeutics
Cross-Over Studies
Protons
Intercellular Signaling Peptides and Proteins
Spine
Safety
Pharmaceutical Preparations

Keywords

  • Contrast
  • Insulin-like growth factor
  • Magnetization transfer
  • MRI
  • Multiple sclerosis
  • Proton MRS
  • TI hypointensities
  • White matter lesion load

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Frank, J. A., Richert, N., Lewis, B., Bash, C., Howard, T., Civil, R., ... Leist, T. (2002). A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients. Multiple Sclerosis, 8(1), 24-29. https://doi.org/10.1191/1352458502ms768oa

A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients. / Frank, J. A.; Richert, N.; Lewis, B.; Bash, C.; Howard, T.; Civil, R.; Stone, R.; Eaton, J.; McFarland, H.; Leist, T.

In: Multiple Sclerosis, Vol. 8, No. 1, 2002, p. 24-29.

Research output: Contribution to journalArticle

Frank, JA, Richert, N, Lewis, B, Bash, C, Howard, T, Civil, R, Stone, R, Eaton, J, McFarland, H & Leist, T 2002, 'A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients', Multiple Sclerosis, vol. 8, no. 1, pp. 24-29. https://doi.org/10.1191/1352458502ms768oa
Frank, J. A. ; Richert, N. ; Lewis, B. ; Bash, C. ; Howard, T. ; Civil, R. ; Stone, R. ; Eaton, J. ; McFarland, H. ; Leist, T. / A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients. In: Multiple Sclerosis. 2002 ; Vol. 8, No. 1. pp. 24-29.
@article{3765c106281b415dad1d7d74ea5575c9,
title = "A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients",
abstract = "The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-I (rhIGF-I) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sclerosis (MS) patients. Monthly clinical and MRI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-I. The primary outcome measure was contrast enhancing lesion (CEL) frequency on treatment compared to baseline. Secondary outcome measures included clinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), TI-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regional metabolite ratios. rhIGF-I (Cephalon) was administered at a dose of 50 mg subcutaneously twice a day for 6 months. rhIGF-I was safe and well tolerated with no severe adverse reactions. There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity. Although rhIGF-I did not alter the course of disease in this small cohort of MS patients, the drug was well tolerated. Further studies using rhIGF-I alone or in combination with other therapies may be of value because of the proposed mechanism of action of this growth factor on the oligodendrocyte and remyelination.",
keywords = "Contrast, Insulin-like growth factor, Magnetization transfer, MRI, Multiple sclerosis, Proton MRS, TI hypointensities, White matter lesion load",
author = "Frank, {J. A.} and N. Richert and B. Lewis and C. Bash and T. Howard and R. Civil and R. Stone and J. Eaton and H. McFarland and T. Leist",
year = "2002",
doi = "10.1191/1352458502ms768oa",
language = "English (US)",
volume = "8",
pages = "24--29",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients

AU - Frank, J. A.

AU - Richert, N.

AU - Lewis, B.

AU - Bash, C.

AU - Howard, T.

AU - Civil, R.

AU - Stone, R.

AU - Eaton, J.

AU - McFarland, H.

AU - Leist, T.

PY - 2002

Y1 - 2002

N2 - The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-I (rhIGF-I) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sclerosis (MS) patients. Monthly clinical and MRI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-I. The primary outcome measure was contrast enhancing lesion (CEL) frequency on treatment compared to baseline. Secondary outcome measures included clinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), TI-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regional metabolite ratios. rhIGF-I (Cephalon) was administered at a dose of 50 mg subcutaneously twice a day for 6 months. rhIGF-I was safe and well tolerated with no severe adverse reactions. There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity. Although rhIGF-I did not alter the course of disease in this small cohort of MS patients, the drug was well tolerated. Further studies using rhIGF-I alone or in combination with other therapies may be of value because of the proposed mechanism of action of this growth factor on the oligodendrocyte and remyelination.

AB - The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-I (rhIGF-I) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sclerosis (MS) patients. Monthly clinical and MRI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-I. The primary outcome measure was contrast enhancing lesion (CEL) frequency on treatment compared to baseline. Secondary outcome measures included clinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), TI-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regional metabolite ratios. rhIGF-I (Cephalon) was administered at a dose of 50 mg subcutaneously twice a day for 6 months. rhIGF-I was safe and well tolerated with no severe adverse reactions. There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity. Although rhIGF-I did not alter the course of disease in this small cohort of MS patients, the drug was well tolerated. Further studies using rhIGF-I alone or in combination with other therapies may be of value because of the proposed mechanism of action of this growth factor on the oligodendrocyte and remyelination.

KW - Contrast

KW - Insulin-like growth factor

KW - Magnetization transfer

KW - MRI

KW - Multiple sclerosis

KW - Proton MRS

KW - TI hypointensities

KW - White matter lesion load

UR - http://www.scopus.com/inward/record.url?scp=18244395081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244395081&partnerID=8YFLogxK

U2 - 10.1191/1352458502ms768oa

DO - 10.1191/1352458502ms768oa

M3 - Article

C2 - 11936485

AN - SCOPUS:18244395081

VL - 8

SP - 24

EP - 29

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 1

ER -